# FT576 in Subjects With Multiple Myeloma

> **NCT05182073** · PHASE1 · COMPLETED · sponsor: **Fate Therapeutics** · enrollment: 31 (actual)

## Conditions studied

- Multiple Myeloma
- Myeloma

## Interventions

- **DRUG:** FT576 (Allogenic CAR NK cells with BCMA expression)
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Daratumumab
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT05182073
- **Lead sponsor:** Fate Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-10
- **Primary completion:** 2024-09-20
- **Final completion:** 2024-10-18
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05182073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05182073, "FT576 in Subjects With Multiple Myeloma". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT05182073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*